Noscira has received US Food and Drug Administration (FDA) fast-track designation for tideglusib (Zentylor) for the treatment of progressive supranuclear palsy, a degenerative brain disorder.
Noscira began Phase II trials of tideglusib in December 2009.
Noscira CEO Belén Sopesén said that fast-track status was an incentive to continue the clinical development of tideglusib for progressive supranuclear palsy, which currently has no treatment options.
The designation is granted to facilitate the development and expedite the review of drugs that treat potentially fatal diseases and meet unmet clinical needs.
Progressive supranuclear palsy affects around five in every 100,000 people.